Skip to main content

Table 1 Clinical and laboratory parameters of all patients, survivors, non-survivors before and during treatment with protein C concentrate

From: Human protein C concentrate in the treatment of purpura fulminans: a retrospective analysis of safety and outcome in 94 pediatric patients

 

All

Survived

(n= 73)

Died

(n= 21)

P

Male/female

(n)

52/42

42/31

10/11

n.s.

Age

(years)

2.46

2.93

1.69

n.s.

PC treatment

PC total dose

(IU/kg)

258.8 (127.6-410.9)

277.8 (132.4-444.4)

153.8 (126.0-375.0)

n.s.

PC daily dose

(IU/kg/d)

100 (73.4-136.6)

100

(78.74-133.3)

81.08 (71.09-153.8)

n.s.

PC therapy duration (d)

2

(1-4)

3

(2-4)

2

(1-4)

n.s.

Bolus/

Bolus + cont. inf.

78/16

61/12

17/4

n.s.

Haematological paramenters prior to PC treatment

WBC

(pl)

10.4

(5.0-17.02)

11.3

(5.3-18.7)

7.21

(4.6-10.75)

n.s (0.062)

CRP

(mg/dl)

10.48

(5.65-16.47)

11.6

(7.81-17.31)

5.9

(1.99-8.92)

0.0018

Platelets

(G/l)

110

(66-183)

116

(74-182)

78

(52-178)

n.s.

PT

(%)

41

(32-54)

44

(33-56)

31

(22-36)

< 0.001

aPTT

(sec.)

59

(43-91)

52

(39-71)

108

(81-160)

< 0.001

Fibrinogen

(mg/dl)

270

(174-440)

347

(217-503)

129

(82-202)

< 0.001

D-Dimers

(mg/l)

2.38

(0.93-8.99)

2.13

(0.89-8.62)

6.40

(1.08-12.00)

n.s.

AT

(%)

76

(57-87)

80

(60-88)

70

(46-80)

n.s.

PC

(%)

27

(14-39)

30

(18-41)

10

(10-18)

< 0.05

Haematological parameters during PC treatment

WBC

(pl)

21.25

(12.75-27.28)

23.65

(13.65-28.75)

16.35

(7.7-20.90)

< 0.05

CRP

(mg/dl)

14.70 (7.0-21.8)

15.91

(7.1-23.64)

9.36

(6.90-15.88)

n.s.

Platelets

(G/l)

96

(57-130)

103

(65.5-136.5)

61

(30-80.75)

< 0.01

PT

(%)

69

(48.5-87)

77.8

(55-91)

45.5

(37.75-55.75)

< 0.01

aPTT

(sec.)

43

(33-52.75)

41

(33-47)

61

(47.5-88.4)

< 0.01

Fibrinogen

(mg/dl)

558.5

(342-747.2)

600.5

(418-766)

214.5

(184-299.2)

< 0.01

D-Dimers

(mg/l)

1.95

(0.8-6.16)

1.6

(0.68-5.96)

2.93

(1.14-6.4)

n.s.

AT

(%)

87

(68.5-102.2)

87

(68-101.5)

78

(70-102)

n.s.

PC

(%)

71

(53.5-108.4)

79

(54.7-106.8)

68.5

(33.75-108.5)

n.s.

  1. Data on patient characteristics, outcome and laboratory findings. Shown as median and inter-quartile range (range between first and third quartile). Note that not all laboratory parameters could be obtained in all patients at each time-point.
  2. aPTT, activated partial thromboplastin time; AT, antithrombin; CRP, C reactive protein; n.s., not significant; PC, protein C; PT, prothrombin time; WBC, white blood cell count.
Back to article page

Critical Care

ISSN: 1364-8535